Analyst Young Li initiated coverage of the maker of ocular implants to resolve vision issues with a buy rating, citing its "unique" technology. "RXST makes the first and only post surgery adjustable intraocular lens to resolve cataracts. The differentiated and best in class tech enables premium [advanced technology intraocular lens] [total addressable expansion], and share taking, from 10% U.S. share to 50%+ U.S. [long term]," the analyst wrote. Checks suggest that nearly half of intraocular lens patients qualify, boosting the firm's confidence in modeling 45% LAL growth by the end of 2025 — ahead of consensus expectations. Jefferies' upside scenario would see share soaring nearly 80% to $90 per share and "assumes above expectations US market expansion of sIOL upgrades, as well as ATIOL share taking."

---

Persons: Jefferies, Young Li, RXST, Li Organizations: RxSight